Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR7 | P34969 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640964 | 0.90 | OPRM1 (0.48) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL13640751 | 0.85 | OPRL1 (0.46) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL13640794 | 0.84 | OPRL1 (0.47) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL13640883 | 0.84 | OPRL1 (0.47) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL13640962 | 0.81 | BACE1 (0.45) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL13640821 | 0.80 | SIGMAR1 (0.47) | OPRL1OPRM1 | |
| SCHEMBL12084376 | 0.80 | OPRL1 (0.44) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL13643831 | 0.79 | OPRL1 (0.44) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL20066071 | 0.76 | MAPK14 (0.46) | OPRL1OPRM1OPRK1BACE1HTR1A | |
| SCHEMBL29709310 | 0.76 | MAPK14 (0.46) | OPRL1OPRM1OPRK1BACE1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | OPRL1 108/4885OPRM1 177/4885OPRK1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.